You are here

Article Text

Article menu

Download PDFPDF

Bone/cartilage biology
Methothrexate directly inhibits RANKL expression and osteoclast formation in very early arthritis
Free
  1. S Revu,
  2. P Neregård,
  3. E af Klint,
  4. A I Catrina
  1. Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden

https://doi.org/10.1136/ard.2010.129593t

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Objective

    Methotrexate (MTX) is one of the most widely used therapies in rheumatoid arthritis (RA) due to its anti-inflammatory and potential bone protection effect. Bone biology is governed by the RANKL/RANK/OPG system that determines the balance between bone formation by osteoblasts and bone resorption by osteoclasts. We investigated the effects of MTX on the RANKL/RANK/OPG system in vivo and in vitro.

    Methods

    16 patients with newly diagnosed RA (mean disease duration 1 week) were started …

    View Full Text